netFormulary
 Report : Medicines with links to NICE 20/11/2019 06:43:57

[Back]

Report looks at the links table and pulls back all the items in the formulary where there is a link with 'nice.org' in the URL

You can sort this table Medicines Link Name or Link URL by clicking on the title

Selecting the Medicine name will take you to the entry in the formulary, Selecting the Link name will follow the link

 
Medicines/Item Section Status Link Name / Link URL
Arsenic Trioxide 08.01.05 Formulary NICE TA526 - Arsenic trioxide for treating acute promyelocytic leukaemia
Telbivudine Tablets 05.03.03.01 Formulary NICE TA154: Telbivudine for the treatment of chronic hepatitis B
Abciximab 02.09 Formulary NICE TA47 - Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes
Abiraterone Tablets 08.03.04.02 Formulary NICE TA259: Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen
Abiraterone Tablets 08.03.04.02 Formulary NICE TA387: Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
Adalimumab 13.05.03 Formulary NICE TA146: Adalimumab for the treatment of adults with psoriasis
Adalimumab 11.08.02 Formulary NICE TA460 - Adalimumab and dexamethasone for treating non-infectious uveitis
Adalimumab 01.05.03 Formulary NICE TA 187: Infliximab (review) and adalimumab for the treatment of Crohn’s disease
Adalimumab 10.01.03 Formulary NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor
Adefovir Dipivoxil Tablets 05.03.03 Formulary NICE CG165: Hepatitis B (chronic) - incorporates TA96
Adefovir Dipivoxil Tablets 05.03.03 Formulary NICE TA96: Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alpha-2a
Afatinib 08.01.05 Formulary Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer
Aflibercept 08.01 Formulary NICE TA 307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy
Aflibercept 11.08.02 Formulary NICE TA305 - Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion
Aflibercept 11.08.02 Formulary NICE TA 294 - Aflibercept solution for injection for treating wet age‑related macular degeneration
Aflibercept 11.08.02 Formulary NICE TA346 - Aflibercept for treating diabetic macular oedema
Aflibercept 11.08.02 Formulary NICE TA409 - Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion
Aflibercept 11.08.02 Formulary NICE TA 486 - Aflibercept for treating choroidal neovascularisation
Alirocumab 02.12 Formulary NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Alitretinoin 13.05.01 Formulary NICE TA177: Alitretinoin for the treatment of severe chronic hand eczema
Alteplase 02.10.02 Formulary NICE TA264: Ischaemic stroke (acute) - alteplase
Anti-D (Rh0) Immunoglobulin 14.05.03 Formulary NICE TA156: Anti-D in pregnant women
Apixaban 02.08.02 Formulary NICE TA275: Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation
Apixaban 02.08.02 Formulary NICE TA341 - Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
Apremilast 10.01.03 Formulary NICE TA433: Apremilast for treating active psoriatic arthritis
Apremilast 13.05.03 Formulary NICE TA433 - Apremilast for treating active psoriatic arthritis
Apremilast 13.05.03 Formulary NICE TA419 - Apremilast for treating moderate to severe plaque psoriasis
Aripiprazole 04.02.01 Formulary NICE TA213: Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years
Aripiprazole 04.02.01 Formulary NICE TA292: Bipolar disorder (children) - aripiprazole (NICE TA292)
Avelumab 10.01.03 Formulary NICE TA517 - Avelumab for treating metastatic Merkel cell carcinoma
Azacitidine Injection 08.01.03 Formulary NICE TA218: Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia
Baricitinib 10.01.03 Formulary Baricitinib for moderate to severe rheumatoid arthritis
Bendamustine 08.01.01 Formulary NICE TA 344: Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia
Bendamustine 08.01.01 Formulary NICE TA216: Bendamustine for the first-line treatment of chronic lymphocytic leukaemia
Bevacizumab Infusion 08.01.05 Formulary NICE TA284: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
Bevacizumab Infusion 08.01.05 Formulary NICE TA 118: Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer
Bevacizumab Infusion 08.01.05 Formulary NICE TA 212: Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer
Bevacizumab Infusion 08.01.05 Formulary NICE TA 242: Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) andpan
Bevacizumab Infusion 08.01.05 Formulary NICE TA 178: Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma
Bevacizumab Infusion 08.01.05 Formulary NICE TA263: Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer
Bevacizumab Infusion 08.01.05 Formulary NICE TA285: Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer
Bevacizumab Infusion 08.01.05 Formulary NICE TA214: Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer
Bivalirudin 02.08.01 Formulary NICE TA230: Bivalirudin for the treatment of STEMI, 2011
Bivalirudin 02.08.01 Formulary NICE CG94: Unstable angina and NSTEMI
Boceprevir Capsules 05.03.03 Formulary NICE Guidance 2012
Bortezomib Injection 08.01.05 Formulary NICE TA228:Bortezomib and thalidomide for the first‑line treatment of multiple myeloma
Bortezomib Injection 08.01.05 Formulary NICE TA 311: Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation
Bortezomib Injection 08.01.05 Formulary NICE TA129: Bortezomib monotherapy for relapsed multiple myeloma
Bosutinib 08.01.05 Formulary NICE TA401 - Bosutinib for previously treated chronic myeloid leukaemia
Botulinum toxin Type A 07.04.02 Formulary NICE CG171:- Urinary incontinence: The management of urinary incontinence in women
Botulinum Toxin Type A 04.07.04.02 Formulary NICE TA260: Botulinum toxin type A for the prevention of headaches in adults with chronic migraine
Brodalumab 10.01.03 Formulary Brodalumab for treating moderate to severe plaque psoriasis
Cabazitaxel Infusion 08.01.05 Formulary NICE TA255: Cabazitaxel for hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen
Cabazitaxel Infusion 08.01.05 Formulary NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
Cabozantinib 08.01.05 Formulary NICE TA463 - Cabozantinib for previously treated advanced renal cell carcinoma
Canagliflozin 06.01.02.03 Formulary NICE TA315:- Canagliflozin in combination therapy for treating type 2 diabetes
Canagliflozin 06.01.02.03 Formulary NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Capecitabine Tablets 08.01.03 Formulary NICE TA212: Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer
Capecitabine Tablets 08.01.03 Formulary NICE TA191: Capecitabine for the treatment of advanced gastric cancer
Capecitabine Tablets 08.01.03 Formulary NICE TA61: Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer
Capecitabine Tablets 08.01.03 Formulary NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
Capecitabine Tablets 08.01.03 Formulary NICE TA263: Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer
Carfilzomib 08.01.05 Formulary NICE TA 457 - Carfilzomib for previously treated multiple myeloma
Carmustine 08.01.01 Formulary NICE TA121: Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma
Carmustine 08.01.01 Formulary NICE TA149: Carmustine implants for the treatment of recurrent glioblastoma multiforme (terminated appraisal)
Ceritinib 08.01.05 Formulary NICE TA500 - Ceritinib for untreated ALK-positive non-small-cell lung cancer
Certolizumab Pegol 10.01.03 Formulary NICE TA186: Rheumatoid arthritis - certolizumab pegol
Cetuximab Injection 08.01.05 Formulary NICE TA176: Cetuximab for the first-line treatment of metastatic colorectal cancer
Cetuximab Injection 08.01.05 Formulary NICE TA172: Cetuximab for the treatment of recurrent and/or metastatic squamous cell cancer of the head and neck
Cetuximab Injection 08.01.05 Formulary NICE TA118: Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer
Cetuximab Injection 08.01.05 Formulary NICE TA145: Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck
Cetuximab Injection 08.01.05 Formulary NICE TA 439 - Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Chlorambucil Tablets 08.01.01 Formulary NICE TA344: Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia
Chlorambucil Tablets 08.01.01 Formulary NICE TA343: Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia
Ciclosporin 11.08 Formulary NICE TA369: Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears
Cinacalcet 09.05.01.02 Formulary NICE TA117: Hyperparathyroidism - cinacalcet
Colistimethate Injection 05.01.07 Formulary NICE TA276 - Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis
Colistimethate sodium 03.12 Formulary NICE TA276: Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis
Crizotinib Capsules 08.01.05 Formulary NICE TA296: Crizotinib for previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene
Dabigatran 02.08.02 Formulary NICE TA249: Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation
Dabigatran 02.08.02 Formulary NICE TA 327 - Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
Daclatasvir 05.03.03.02 Formulary NICE TA364 - Daclatasvir for treating chronic hepatitis C
Daclizumab 08.02 Formulary NICE TA 441 - Daclizumab for treating relapsing–remitting multiple sclerosis
Dapagliflozin 06.01.02.03 Formulary NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes
Dapagliflozin 06.01.02.03 Formulary NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Daratumumab 08.01.05 Formulary NICE TA510 - Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
Dasatinib Tablets 08.01.05 Formulary NICE TA251: Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia
Dasatinib Tablets 08.01.05 Formulary NICE TA241: Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML) (part review of NICE technology appraisal guidance 70), and dasatinib and nilotinib for people with CML for whom treatment with
Decitabine Injection 08.01.03 Formulary NICE TA270: Leukaemia (acute myeloid ) - decitabine (terminated appraisal) (TA270)
Degarelix 08.03.04.02 Formulary NICE TA404:- Degarelix for treating advanced hormone-dependent prostate cancer
Denosumab 06.06.02 Formulary NICE TA204: Denosumab for the prevention of osteoporotic fractures in postmenopausal women
Denosumab 06.06.02 Formulary NICE TA265: Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours
Dexamethasone intravitreal implant 11.04.01 Formulary NICE TA229: Dexamethasone intravitreal implant for the treatment of macular oedema
Diltiazem Cream 2% - ANOHEAL 01.07.04 Formulary NICE Advice: Chronic anal fissure: 2% topical diltiazem hydrochloride
Dimethyl fumarate 13.05.03 Formulary NICE TA475 - Dimethyl fumarate for treating moderate to severe plaque psoriasis
Docetaxel Infusion 08.01.05 Formulary NICE TA101: Docetaxel for the treatment of hormone-refractory metastatic prostate cancer
Docetaxel Infusion 08.01.05 Formulary NICE TA109: Docetaxel for the adjuvant treatment of early node-positive breast cancer
Domperidone 04.06 Formulary NICE: Promoting tolerance of enteral feeds in children and young people: domperidone
Donepezil 04.11 Formulary NICE TA217: Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease
Doxorubicin Hydrochloride 08.01.02 Formulary NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Doxorubicin Hydrochloride 08.01.02 Formulary NICE TA91:Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer
Dronedarone 02.03.02 Formulary NICE TA197: Atrial fibrillation - dronedarone
Edoxaban 02.08.02 Formulary NICE TA354: Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism
Edoxaban 02.08.02 Formulary NICE TA355: Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation
Eltrombopag Tablets 09.01.04 Formulary NICE TA293: Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura
Eluxadoline 01.05 Formulary NICE TA 471 - Eluxadoline for treating irritable bowel syndrome with diarrhoea
Empagliflozin 06.01.02.03 Formulary Empagliflozin in combination therapy for treating type 2 diabetes
Empagliflozin 06.01.02.03 Formulary NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Entecavir Tablets 05.03.03 Formulary NICE TA153: Hepatitis B (chronic) - etecavir
Entecavir Tablets 05.03.03 Formulary NICE CG165: Hepatitis B (incorporates TA153)
Enzalutamide 08.03.04.02 Formulary NICE TA377: Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
Eplerenone 02.02.03 Formulary NICE CG108: Chronic heart failure
Eribulin Injection 08.01.05 Formulary NICE TA250: Eribulin for the treatment of locally advanced or metastatic breast cancer
Erlotinib Tablets 08.01.05 Formulary NICE TA 227: Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer
Erlotinib Tablets 08.01.05 Formulary NICE TA 258: Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer
Erlotinib Tablets 08.01.05 Formulary NICE TA227: Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer
Erlotinib Tablets 08.01.05 Formulary NICE TA162: Erlotinib for the treatment of non-small-cell lung cancer
Etanercept 13.05.03 Formulary NICE TA103: Etanercept and efalizumab for the treatment of adults with psoriasis
Etanercept 10.01.03 Formulary NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor
Etanercept 10.01.03 Formulary NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab
Etanercept 10.01.03 Formulary NICE TA35: Arthritis (juvenile idiopathic) - etanercept
Everolimus Tablets 08.01.05 Formulary NICE TA432: Everolimus for advanced renal cell carcinoma after previous treatment
Everolimus Tablets 08.01.05 Formulary NICE TA219: Everolimus for the second-line treatment of advanced renal cell carcinoma
Everolimus Tablets 08.01.05 Formulary NICE TA295: Everolimus in combination with exemestane for treating advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therap
Evolocumab 02.12 Formulary NICE TA 394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Exenatide 06.01.02.03 Formulary NICE CG87:- Type 2 diabetes: The management of type 2 diabetes
Exenatide MR 06.01.02.03 Formulary NICE TA248: Exenatide prolonged-release suspension for injection in combination with oral antidiabetic therapy for the treatment of type 2 diabetes
Ezetimibe 02.12 Formulary NICE TA385 - Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia
Febuxostat 10.01.04 Formulary NICE TA164: Hyperuricaemia - febuxostat
Finasteride 5mg 06.04.02 Formulary NICE CG97: Lower urinary tract symptoms: The management of lower urinary tract symptoms in men
Fingolimod 08.02.04 Formulary NICE TA254: Fingolimod for highly active relapsing remitting multiple sclerosis
Fludarabine Phosphate 08.01.03 Formulary NICE TA29: Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia
Fludarabine Phosphate 08.01.03 Formulary NICE TA119: Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia
Fludrocortisone Acetate 06.03.01 Formulary NICE Evidence Summary - Postural hypotension in adults: fludrocortisone
Fluocinolone intravitreal implant 11.04.01 Formulary NICE TA 301 - Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy
Fluorouracil Injection 08.01.03 Formulary NICE TA 212: Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer
Fluorouracil Injection 08.01.03 Formulary NICE TA 307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy
Fulvestrant 08.03.04.01 Non Formulary NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer
Galantamine 04.11 Formulary NICE TA217: Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease
Gefitinib Tablets 08.01.05 Formulary NICE TA192: Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer
Gemcitabine Injection 08.01.03 Formulary NICE TA 285: Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer
Gemcitabine Injection 08.01.03 Formulary NICE TA25: Guidance on the use of gemcitabine for the treatment of pancreatic cancer
Gemcitabine Injection 08.01.03 Formulary NICE TA116: Gemcitabine for the treatment of metastatic breast cancer
Gemcitabine Injection 08.01.03 Formulary NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Gemcitabine Injection 08.01.03 Formulary NICE TA360: Paclitaxel as albumin-bound nanoparticles in combination with gemcitabine for previously untreated metastatic pancreatic cancer
Glecaprevir–pibrentasvir 05.03.03.02 Formulary NICE TA499 - Glecaprevir–pibrentasvir for treating chronic hepatitis C
GLIADEL wafer Carmustine 7.6mg 17 Non Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Golimumab 10.01.03 Formulary NICE TA220: Psoriatic arthritis - golimumab
Golimumab 10.01.03 Formulary NICE TA233: Ankylosing spondylitis - golimumab
Golimumab 10.01.03 Formulary NICE TA225: Rheumatoid arthritis - golimumab
Ibrutinib 08.01.05 Formulary NICE TA 502 - Ibrutinib for treating relapsed or refractory mantle cell lymphoma
Ibrutinib 08.02.03 Formulary NICE TA429: Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
Idelalisib 08.01.05 Formulary NICE TA 359:- Idelalisib for treating chronic lymphocytic leukaemia
Imatinib Tablets 08.01.05 Formulary NICE TA86: Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours
Imatinib Tablets 08.01.05 Formulary NICE TA236: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
Imatinib Tablets 08.01.05 Formulary NICE TA70: Guidance on the use of imatinib for chronic myeloid leukaemia
Imatinib Tablets 08.01.05 Formulary NICE TA209: Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours
Imatinib Tablets 08.01.05 Formulary NICE TA241: Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML) (part review of NICE technology appraisal guidance 70), and dasatinib and nilotinib for people with CML for whom treatment with
Imatinib Tablets 08.01.05 Formulary NICE TA326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
Imatinib Tablets 08.01.05 Formulary NICE TA251: Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia
Infliximab 10.01.03 Formulary NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor
Infliximab 10.01.03 Formulary NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab
Infliximab 01.05.03 Formulary NICE TA163: Ulcerative colitis (acute manifestations) Infliximab
Infliximab 01.05.03 Formulary NICE TA140: Ulcerative colitis (subacute manifestations) Infliximab
Infliximab 01.05.03 Formulary NICE TA187: Crohns disease - infliximab (review) and adalimumab (review of TA40)
Infliximab 13.05.03 Formulary NICE TA134: Infliximab for the treatment of adults with psoriasis
Ipilimumab Infusion 08.01.05 Formulary NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
Ipilimumab Infusion 08.01.05 Formulary NICE TA 319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
Irinotecan Injection 08.01.05 Formulary NICE TA 307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy
Ivabradine 02.06.03 Formulary NICE CG126: Management of stable angina
Ixekizumab 13.05.02 Formulary NICE TA 442 - Ixekizumab for treating moderate to severe plaque psoriasis
Lapatinib Tablets 08.01.05 Formulary NICE TA257: Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2
Ledipasvir- sofosbuvir 05.03.03.02 Formulary NICE TA363 - Ledipasvir–sofosbuvir for treating chronic hepatitis C
Lenvatinib 08.01.05 Formulary NICE TA 498 - Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
Linaclotide 01.06.07 Formulary NICE CG61: Irritable bowel syndrome in adults: diagnosis and management
Linaclotide 01.06.07 Formulary NICE ESNM 16; Irritable bowel syndrome with constipation in adults: linaclotide
Liraglutide 06.01.02.03 Formulary NICE NG28: Type 2 diabetes in adults: management
Lubiprostone 01.06.07 Formulary NICE TA 318: Lubiprostone for treating chronic idiopathic constipation
Magnesium Glycerophosphate 09.05.01.03 Formulary NICE: Evidence Summary: Magnesium glycerophosphate
Mannitol inhalation 03.07 Formulary NICE TA266: Cystic fibrosis - mannitol dry powder for inhalation (TA266)
Memantine 04.11 Formulary NICE TA217: Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease
Mepolizumab 03.04.03 Formulary NICE TA431: Mepolizumab for treating severe refractory eosinophilic asthma
Methylprednisolone Tablets 06.03.02 Non Formulary NICE CG186: Multiple sclerosis: management of multiple sclerosis in primary and secondary care
MIDODRINE Tablets 2.5 mg, 5mg 17 Non Formulary NICE: Postural hypotension in adults: midodrine (ESUOM5)
Midostaurin 08.01.05 Formulary NICE TA523 - Midostaurin for untreated acute myeloid leukaemia
Mifamurtide Infusion 08.02.04 Formulary Mifamurtide for the treatment of osteosarcoma (October 2011)
Mirabegron 07.04.02 Formulary NICE TA290: Mirabegron for overactive bladder
Modafinil 04.04 Formulary NICE: Evidence Summary (Apr 2013)
Nalmefene 04.10.01 Formulary NICE TA 325 - Nalmefene for reducing alcohol consumption in people with alcohol dependence
Naloxegol 01.06.06 Formulary NICE TA 345 - Naloxegol for treating opioid‑induced constipation
Naltrexone 04.10.03 Formulary NICE TA115: Naltrexone for the management of opioid dependence
Natalizumab 08.02.04 Formulary NICE TA127: Multiple sclerosis - natalizumab
Nilotinib Capsules 08.01.05 Formulary NICE TA241: Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML) (part review of NICE technology appraisal guidance 70), and dasatinib and nilotinib for people with CML for whom treatment with
Nilotinib Capsules 08.01.05 Formulary NICE TA251: Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia
Nintedanib 08.01.05 Formulary NICE TA347 - Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer
Obeticholic acid 01.09.01 Formulary NICE TA 443 -Obeticholic acid for treating primary biliary cholangitis
Obinutuzumab 08.02.03 Formulary NICE TA343 - Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia
Ocriplasmin 11.08.02 Formulary NICE TA297: Ocriplasmin for treating vitreomacular traction
Olaparib 08.01.05 Formulary NICE TA 381 - Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy
Omalizumab 13.05.03 Formulary NICE TA339: Omalizumab for previously treated chronic spontaneous urticaria
Omalizumab 03.04.02 Formulary NICE TA201: Omalizumab for the treatment of severe persistent allergic asthma in children aged 6–11
Omalizumab 03.04.02 Formulary NICE TA133: Omalizumab for severe persistent allergic asthma
Omalizumab 03.04.02 Formulary NICE TA339: Omalizumab for previously treated chronic spontaneous urticaria
Ombitasvir-paritaprevir-ritonavir 05.03.03.02 Formulary Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C
Omega-3-Acid Ethyl Esters 02.12 Non Formulary NICE: schizophrenia - omega-3 fatty acid medicines
Omega-3-Marine Triglycerides 02.12 Non Formulary NICE: schizophrenia - omega-3 fatty acid medicines
Osimertinib 08.01.05 Formulary NICE TA416 - Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer
Oxaliplatin 08.01.05 Formulary NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
Paclitaxel - Albumin Bound Formulation 08.01.05 Formulary Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
Paclitaxel Injection 08.01.05 Formulary NICE TA 360: Paclitaxel as albumin-bound nanoparticles in combination with gemcitabine for previously untreated metastatic pancreatic cancer
Paclitaxel Injection 08.01.05 Formulary NICE TA 91: Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer
Paclitaxel Injection 08.01.05 Formulary NICE TA 284: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
Paclitaxel Injection 08.01.05 Formulary NICE TA55: Guidance on the use of paclitaxel in the treatment of ovarian cancer
Paclitaxel Injection 08.01.05 Formulary NICE TA108: Paclitaxel for the adjuvant treatment of early node-positive breast cancer
Paclitaxel Injection 08.01.05 Formulary NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Palbociclib 08.01.05 Formulary NICE 495 - Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Panitumumab 08.01.05 Formulary Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and panitumumab (mo
Panitumumab 08.01.05 Formulary NICE TA 439 - Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Panobinostat 08.01.05 Formulary NICE TA380 - Panobinostat for treating multiple myeloma after at least 2 previous treatments
Pazopanib Tablets 08.01.05 Formulary NICE TA215: Pazopanib for the first-line treatment of advanced renal cell carcinoma
Pegaptanib Sodium 11.08.02 Non Formulary NICE guidance on pegaptanib in AMD (August 2008)
Pegaspargase 08.01.05 Formulary NICE TA408 - Pegaspargase for treating acute lymphoblastic leukaemia
Peginterferon Alfa 08.02.04 Formulary NICE TA106: Hepatitis C - peginterferon alfa & ribavirin
Peginterferon Alfa 08.02.04 Formulary NICE TA 200: Hepatitis C - peginterferon alfa & ribavirin
Peginterferon Alfa 08.02.04 Formulary NICE TA75: Hepatitis C - pegylated interferons, ribavirin & alfa interferon
Peginterferon Alfa 08.02.04 Non Formulary NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon
Peginterferon Alfa 08.02.04 Non Formulary NICE TA200: Hepatitis C - peginterferon alfa and ribavirin
Peginterferon Alfa 08.02.04 Non Formulary NICE TA106: Hepatitis C - peginterferon alfa and ribavirin
Pegloticase 17 Non Formulary NICE TA291: Pegloticase not recommended for severe chronic gout
Pembrolizumab 08.01.05 Formulary NICE TA 357:- Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab
Pemetrexed Injection 08.01.03 Formulary NICE TA190: Pemetrexed for the maintenance treatment of non-small-cell lung cancer
Pemetrexed Injection 08.01.03 Formulary NICE TA181: Pemetrexed for the first-line treatment of non-small-cell lung cancer
Pemetrexed Injection 08.01.03 Formulary NICE TA135: Pemetrexed for the treatment of malignant pleural mesothelioma
Pemetrexed Injection 08.01.03 Formulary NICE TA124: Pemetrexed for the treatment of non-small-cell lung cancer
Pemetrexed Injection 08.01.03 Formulary NICE TA 309: Pemetrexed maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer
Perampanel 04.08.01 Formulary NICE evidence summary - Partial-onset seizures in epilepsy: perampanel as adjunctive treatment
Pimecrolimus 13.05.03 Formulary NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
pirfenidone 17 Non Formulary NICE TA282: Idiopathic pulmonary fibrosis - pirfenidone (TA282)
Pirfenidone 03.12 Formulary Idiopathic pulmonary fibrosis - pirfenidone (TA282)
Ponatinib 08.01.05 Formulary Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
Prasugrel 02.09 Formulary NICE TA317 - Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes
Pregabalin 04.07.03 Formulary Neuropathic pain – pharmacological management: The pharmacological management of neuropathic pain in adults in non-specialist settings
Prucalopride 01.06.07 Formulary NICE TA211: Constipation (women) - prucalopride
Raloxifene Hydrochloride 06.04.01.01 Formulary NICE quick reference guide on osteoporosis
Raltitrexed Injection 08.01.03 Formulary NICE CG 131:- Colorectal cancer: diagnosis and management
Ranibizumab 11.08.02 Formulary NICE TA 155: Ranibizumab and pegaptanib for the treatment of age-related macular degeneration
Ranibizumab 11.08.02 Formulary NICE TA298 - Ranibizumab for treating choroidal neovascularisation associated with pathological myopia
Ranibizumab 11.08.02 Formulary NICE TA 274: Ranibizumab for treating diabetic macular oedema
Ranibizumab 11.08.02 Formulary NICE TA283: Macular oedema (retinal vein occlusion) - ranibizumab: guidance
Ranolazine 02.06.03 Formulary NICE CG 126: Management of stable angina
Regorafenib 08.01.05 Formulary Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
Regorafenib 08.01.05 Formulary Regorafenib for previously treated advanced hepatocellular carcinoma
Reslizumab (Cinqaero®) 03.04.02 Formulary NICE TA479:- Reslizumab for treating severe eosinophilic asthma
Retigabine 04.08.01 Non Formulary NICE TA232: Retigabine for the adjunctive treatment of adults with partial onset seizures in epilepsy with and without secondary generalisation
Ribavirin Capsules 05.03.05 Formulary NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C
Ribavirin Capsules 05.03.05 Formulary NICE TA200: Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C
Ribavirin Capsules 05.03.05 Formulary NICE TA106: Hepatitis C - peginterferon alfa and ribavirin
Ribavirin Capsules 05.03.05 Formulary NICE TA300: Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people
Ribociclib 08.01.05 Formulary NICE TA 496 - Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Rifaximin 05.01.07 Formulary NICE TA 337 - Rifaximin for preventing episodes of overt hepatic encephalopathy
Riluzole 04.09.03 Formulary NICE TA20: Guidance on the Use of Riluzole (Rilutek) for the Treatment of Motor Neurone Disease
Rituximab 08.02.03 Formulary NICE TA243: Rituximab for the first-line treatment of stage III-IV follicular lymphoma
Rituximab 08.02.03 Formulary NICE TA174: Rituximab for the first-line treatment of chronic lymphocytic leukaemia
Rituximab 08.02.03 Formulary NICE TA137: Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma
Rituximab 08.02.03 Formulary NICE TA193: Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia
Rituximab 08.02.03 Formulary NICE TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
Rituximab 08.02.03 Formulary NICE TA308: Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis
Rituximab 08.02.03 Formulary NICE TA65: Rituximab for aggressive non-Hodgkin’s lymphoma
Rituximab 08.02.03 Formulary NICE TA226: Rituximab for the first-line maintenance treatment of follicular non-Hodgkin’s lymphoma
Rituximab (rheumatology) 10.01.03 Formulary NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor
Rivaroxaban 02.08.02 Formulary NICE TA256: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation
Rivaroxaban 02.08.02 Formulary NICE TA335 - Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome
Rivaroxaban 02.08.02 Formulary NICE TA261: Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism
Rivaroxaban 02.08.02 Formulary NICE TA287: Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism
Rivastigmine 04.11 Formulary NICE TA217: Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease
Roflumilast 03.03.03 Formulary NICE Final Appraisal Determination Dec 2011
Roflumilast 03.03.03 Formulary NICE TA 244:- Roflumilast for the management of severe chronic obstructive pulmonary disease
Roflumilast 03.03.03 Formulary NICE TA 461 - Roflumilast for treating chronic obstructive pulmonary disease
Romiplostim Injection 09.01.04 Formulary NICE TA221: Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura
Ruxolitinib 08.01.05 Formulary NICE TA 289: Ruxolitinib for disease-related splenomegaly or symptoms in adults with myelofibrosis
Sacubitril valsartan 02.05.05.02 Formulary NICE TA388:- Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction
Secukinumab 13.05.03 Formulary NICE TA407 - Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors
Secukinumab 13.05.03 Formulary NICE TA350: Secukinumab for treating moderate to severe plaque psoriasis
Sofosbuvir-velpatasvir 05.03.03 Formulary NICE TA430: Sofosbuvir–velpatasvir for treating chronic hepatitis C
Sofosbuvir-velpatasvir-voxilaprevir 05.03.03.02 Formulary NICE TA507 - Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C
Somatropin 06.05.01 Formulary NICE TA188: Human growth hormone (somatropin) for the treatment of growth failure in children (review)
Somatropin 06.05.01 Formulary NICE TA64: Growth hormone deficiency (adults) - human growth hormone
Sorafenib Tablets 08.01.05 Formulary NICE TA189: Sorafenib for the treatment of advanced hepatocellular carcinoma
Sorafenib Tablets 08.01.05 Formulary NICE TA178: Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma
Sunitinib Capsules 08.01.05 Formulary NICE TA179: Sunitinib for the treatment of gastrointestinal stromal tumours
Sunitinib Capsules 08.01.05 Formulary NICE TA178: Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma
Sunitinib Capsules 08.01.05 Formulary NICE TA169: Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma
Sunitinib Capsules 08.01.05 Formulary NICE TA 189: Sorafenib for the treatment of advanced hepatocellular carcinoma
Tacrolimus 13.05.03 Formulary NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
Tadalafil 07.04.05 Formulary NICE TA273: Hyperplasia (benign prostatic) - tadalafil (terminated appraisal) (TA273)
Talimogene laherparepvec 08.01.05 Formulary NICE TA410 - Talimogene laherparepvec for treating unresectable metastatic melanoma
Tegafur with Uracil 08.01.03 Formulary NICE TA61: Capcitabine and tegafur - Colorectal cancer
Telaprevir Tablets 05.03.03 Formulary NICE Guidance 2012
Temozolomide Capsules 08.01.05 Formulary NICE TA23: Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer)
Temozolomide Capsules 08.01.05 Formulary NICE TA121: Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma
Temsirolimus Infusion 08.01.05 Formulary NICE TA207: Temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma (terminated appraisal)
Temsirolimus Infusion 08.01.05 Formulary NICE TA178: Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma
Tenofovir Disproxil Tablets 05.03.01 Formulary NICE CG165: Hepatitis B (chronic) : diagnosis and management
Tenofovir Disproxil Tablets 05.03.01 Formulary NICE CG173: Tenofovir disoproxil for the treatment of chronic hepatitis B
Teriparatide 06.06.01 Formulary NICE TA161: Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (amended)
Teriparatide 06.06.01 Formulary NICE TA 160 - Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women
Ticagrelor 02.09 Formulary NICE TA 420 - Ticagrelor for preventing atherothrombotic events after myocardial infarction
Ticagrelor 02.09 Formulary NICE TA 236 - Ticagrelor for the treatment of acute coronary syndromes
Tivozanib 08.01.05 Formulary Tivozanib for treating advanced renal cell carcinoma
Tobramycin inhaler 05.01.04 Formulary NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin (TA276)
Tocilizumab 10.01.03 Formulary NICE TA247 - Tocilizumab for the treatment of rheumatoid arthritis
Tocilizumab 10.01.03 Formulary NICE TA 373 - Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Tocilizumab 10.01.03 Formulary NICE TA 375 - Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Tocilizumab 10.01.03 Formulary NICE TA 238 - Tocilizumab for the treatment of systemic juvenile idiopathic arthritis
Tofacitinib 10.02.01 Formulary Tofacitinib for moderate to severe rheumatoid arthritis
Topotecan 08.01.05 Formulary NICE TA91: Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer
Topotecan 08.01.05 Formulary NICE TA183: Topotecan for the treatment of recurrent and stage IVB cervical cancer
Topotecan 08.01.05 Formulary NICE TA184:Topotecan for the treatment of relapsed small-cell lung cancer
Topotecan 08.01.05 Formulary NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Trabectedin Injection 08.01.05 Formulary NICE TA185: Trabectedin for the treatment of advanced soft tissue sarcoma
Trabectedin Injection 08.01.05 Formulary NICE TA222: Trabectedin for the treatment of relapsed ovarian cancer
Trabectedin Injection 08.01.05 Formulary NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Trastuzumab emtansine 08.01.05 Formulary Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane
Trastuzumab Infusion 08.01.05 Formulary NICE TA257: Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2
Trastuzumab Infusion 08.01.05 Formulary NICE TA 107: Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer
Trastuzumab Infusion 08.01.05 Formulary NICE TA34: Guidance on the use of trastuzumab for the treatment of advanced breast cancer
Trastuzumab Infusion 08.01.05 Formulary NICE TA208: Trastuzumab for the treatment of HER2-positive metastatic gastric cancer
Trifluridine-tipiracil Tablets 08.01.03 Formulary NICE TA405 - Trifluridine–tipiracil for previously treated metastatic colorectal cancer
Ustekinumab 13.05.03 Formulary NICE TA180: Ustekinumab for the treatment of adults with moderate to severe psoriasis
Ustekinumab (rheumatology) 10.01.03 Formulary NICE TA340 - Ustekinumab for treating active psoriatic arthritis
Varenicline 04.10.02 Formulary NICE TA123: Varenicline
Vedolizumab 01.05.03 Formulary NICE TA 342 - Vedolizumab for treating moderately to severely active ulcerative colitis
Vemurafenib Tablets 08.01.05 Formulary NICE TA269: Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma
Venetoclax 08.01.05 Formulary NICE TA 487 - Venetoclax for treating chronic lymphocytic leukaemia
Verteporfin 11.08.02 Formulary NICE TA68 - Guidance on the use of photodynamic therapy for age-related macular degeneration
Vinflunine 08.01.04 Non Formulary NICE TA272: Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine (TA272)
Vortioxetine 04.03.03 Formulary NICE TA367: Vortioxetine for treating major depressive episodes
Zolpidem 04.01.01 Formulary NICE TA77: Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia
Zopiclone 04.01.01 Formulary NICE TA77: Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia
NHS Birmingham and Solihull
Clinical Commissioning Group